A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results